Radiance
Register
Register
Register

Project cooperationUpdated on 26 June 2025

Preclinical Immuno-modulatory Drug Development in Oncology

Marc Creus

CEO at abbmira therapeutics AG

Basel, Switzerland

About

The native immune system and particularly tumor associated macrophages (TAMs) are critical in driving response to cancer therapies. Abbmira designs novel synthetic small molecule compounds against a specific molecular target of macrophages that activate TAMs to exert direct anti-tumoral action, whilst signaling to the rest of the immune system to fight the cancer also.

Stage

  • Proposal Idea
  • Proposal under Development

Topic

  • MSCA-POSTDOCTORAL FELLOWSHIPS
  • MSCA-DOCTORAL NETWORKS

Type

  • POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
  • DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)

Organisation

abbmira therapeutics AG

Company (SME, Spin-off, Start-up)

Basel, Switzerland

Similar opportunities